In a first trial of androgen receptor inhibitor, enzalutamide alone or combined with an aromatase inhibitor in women with advanced breast cancer, pharmacokinetics and tolerability of single agentenzalutamide have shown to be similar to that reported in men.

Estradiol remained low in combination with exemestane, according to the results presented by Dr Tiffany Traina of the Memorial Sloan-Kettering Cancer Center, New York, USA.

Read the article in full here

Source: ESMO